OS Therapies (OSTX) Common Equity (2023 - 2026)
OS Therapies' (OSTX) quarterly Common Equity came in at -$10.8 million in Q1 2026, down 158.55% YoY from $18.5 million in Q1 2025, and down 77.57% on a QoQ basis from -$6.1 million in Q4 2025.
OS Therapies (OSTX) Common Equity (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Common Equity data on file, last reported at -$10.8 million in Q1 2026.
- Quarterly Common Equity fell 158.55% year-over-year to -$10.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10.8 million (down 158.55% YoY) and the FY2025 annual result came in at -$6.1 million, down 86.61% from the prior year.
- Common Equity retreated to -$10.8 million in Q1 2026, from -$6.1 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $4.9 million in Q2 2025 to a low of -$27.1 million in Q2 2024.
- A 4-year average of -$12.0 million and a median of -$10.8 million in 2026 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity jumped 614.36% — and 2026, when it plunged 158.55%.
- Tracing OSTX's Common Equity over 4 years: stood at -$24.0 million in 2023, then surged by 86.4% to -$3.3 million in 2024, then plunged by 86.61% to -$6.1 million in 2025, then plunged by 77.57% to -$10.8 million in 2026.
- The last three Common Equity figures came in at -$10.8 million (Q1 2026), -$6.1 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.04 Bn | 130.18 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.98 Bn | 77.98 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.37 Bn | 59.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.75 Bn | 9.35 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.24 Bn | 26.08 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.03 Bn | 26.20 Bn | - | 9.79 Bn |
| 10 | OS Therapies | 19.31 Mn | 19.31 Mn | - | -11.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.82 Mn |
| Dec 31, 2025 | -6.10 Mn |
| Sep 30, 2025 | 3.64 Mn |
| Jun 30, 2025 | 4.94 Mn |
| Mar 31, 2025 | -4.19 Mn |
| Dec 31, 2024 | -3.27 Mn |
| Sep 30, 2024 | -707,128.00 |
| Jun 30, 2024 | -27.06 Mn |
| Mar 31, 2024 | -25.51 Mn |
| Dec 31, 2023 | -24.02 Mn |
| Sep 30, 2023 | -22.52 Mn |
| Jun 30, 2023 | -21.27 Mn |
| Mar 31, 2023 | -18.74 Mn |